Carfilzomib, Dexamethasone, and Daratumumab Myeloma Treatment Alternative
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, talks about the use of carfilzomib, dexamethasone, and daratumumab as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, a consultant clinical and laboratory hematologist at St. Vincent’s Hospital in East Melbourne, Australia talks about the use of carfilzomib (Kyprolis), dexamethasone, and daratumumab (Darzalex) as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.
Lenalidomide and bortezomib are often used to treat patients with newly-diagnosed multiple myeloma. However, many patients progress while on these agents or discontinue them due to toxicity. According to Quach, not all jurisdictions are able to afford the higher cost combination of carfilzomib and lenalidomide. Therefore, a more affordable yet equally effective alternative must be found.
The study, which was presented at the 62nd American Society of Hematology Meeting and Exposition, is a collaboration between the Asian Myeloma Network and the Australian Leukemia Myeloma Group.
Peers Discuss Role of Pola-R-CHP vs R-CHOP in Newly Diagnosed DLBCL
April 19th 2024During a Case-Based Roundtable® event, Haifaa Abdulhaq, MD discussed with participants whether the POLARIX trial influences their choice to use the pola-R-CHP as opposed to R-CHOP regimen for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
